LENZ Therapeutics (LENZ) to Release Earnings on Wednesday

LENZ Therapeutics (NASDAQ:LENZ - Get Free Report) is set to post its quarterly earnings results before the market opens on Wednesday, November 6th. Analysts expect LENZ Therapeutics to post earnings of ($0.47) per share for the quarter.

LENZ Therapeutics (NASDAQ:LENZ - Get Free Report) last announced its quarterly earnings results on Wednesday, August 14th. The company reported ($0.40) earnings per share for the quarter, beating analysts' consensus estimates of ($0.49) by $0.09. On average, analysts expect LENZ Therapeutics to post $-3 EPS for the current fiscal year and $-3 EPS for the next fiscal year.

LENZ Therapeutics Stock Down 2.5 %

Shares of LENZ traded down $0.68 during mid-day trading on Thursday, reaching $26.96. The company had a trading volume of 153,382 shares, compared to its average volume of 134,652. The firm has a fifty day simple moving average of $23.83 and a 200-day simple moving average of $20.62. LENZ Therapeutics has a fifty-two week low of $14.07 and a fifty-two week high of $31.00.

Analysts Set New Price Targets

Several equities analysts recently weighed in on the stock. HC Wainwright assumed coverage on shares of LENZ Therapeutics in a report on Monday, August 12th. They set a "buy" rating and a $38.00 target price on the stock. William Blair raised shares of LENZ Therapeutics to a "strong-buy" rating in a research note on Friday, August 30th. Raymond James began coverage on shares of LENZ Therapeutics in a research note on Friday, September 27th. They set an "outperform" rating and a $37.00 price target on the stock. Finally, Piper Sandler reaffirmed an "overweight" rating and set a $36.00 price target on shares of LENZ Therapeutics in a research note on Thursday, August 15th. Six equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, the company presently has an average rating of "Buy" and an average price target of $35.40.

About LENZ Therapeutics

LENZ Therapeutics, Inc, a biopharmaceutical company, focuses on developing and commercializing therapies to improve vision in the United States. Its product candidates include LNZ100 and LNZ101 which are in Phase III clinical trials for the treatment of presbyopia. The company is headquartered in Del Mar, California.